You are here

Ridgeback Biotherapeutics

ICER says Pfizer's Paxlovid, Merck's molnupiravir both cost effective, but their benefits are far from equal

Fierce Pharma

Tue, 05/10/22 - 10:50 am

Ridgeback Biotherapeutics

New Studies Support Benefit of Merck's Molnupiravir

BioSpace

Mon, 04/4/22 - 11:13 pm

Ridgeback Biotherapeutics

clinical trials

Merck’s Anti-Covid Pill Shows Better Effectiveness In Indian Study

Forbes

Sun, 02/20/22 - 11:56 am

Ridgeback Biotherapeutics

FDA panel narrowly recommends authorization of first antiviral pill to treat Covid-19

Stat

Tue, 11/30/21 - 11:35 pm

Ridgeback Biotherapeutics

Merck’s Molnupiravir: When a Private-Public Partnership Bears Fruit

BioSpace

Wed, 11/3/21 - 11:33 pm

Ridgeback Biotherapeutics

EMA starts rolling review of Merck's molnupiravir, continuing rapid regulatory response to COVID-19 antiviral data

Fierce Biotech

Mon, 10/25/21 - 10:58 am

Ridgeback Biotherapeutics

Could a New COVID Pill Crush Vaccine Sales?

Motley Fool

Tue, 10/5/21 - 10:45 am

Ridgeback Biotherapeutics

This Biopharma Giant May Have Just Found Its Ticket To Riches In the COVID-19 Market

Motley Fool

Thu, 06/17/21 - 10:50 am

Ridgeback Biotherapeutics

Scientists work toward an elusive dream: a simple pill to treat Covid-19

Stat

Fri, 04/9/21 - 10:56 am

drug development

Ridgeback Biotherapeutics

Atea Pharmaceuticals

Merck reports positive early data for its experimental COVID-19 pill

Beckers Hospital Review

Mon, 03/8/21 - 09:30 pm

Ridgeback Biotherapeutics

clinical trials

FDA greenlights second Ebola treatment in three months, handing new OK to Ridgeback's Ebanga

Endpoints

Tue, 12/22/20 - 10:46 am

Ridgeback Biotherapeutics